Jasmine Harley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jasmine Harley has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Charlotte Spicer
Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK
1 shared publication - J. Paul Taylor
St Jude Children's Research Hospital
1 shared publication - Linda Greensmith
Department of Neuromuscular Diseases, UCL Institute of Neurology, London, UK
1 shared publication - Mhoriam Ahmed
Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK
1 shared publication - Michael G. Hanna
MRC Centre for Neuromuscular Disease, UCL Institute of Neurology, Queen Square, London, UK
1 shared publication - Rickie Patani
The Francis Crick Institute, 1 Midland Road, London, UK
1 shared publication
Latest Publications
- Open Access
- 29 July 2023
- Published by Springer Nature in Molecular Neurobiology
- Vol. 60 (12) , 6896-6915
Amplifying the Heat Shock Response Ameliorates ALS and FTD Pathology in Mouse and Human Models
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are now known as parts of a disease spectrum with common pathological features and genetic causes. However, as both conditions are clinically heterogeneous, patient groups may be phenotypically similar but pathogenically and genetically variable. Despite numerous clinical trials, there remains no effective therapy for these conditions, which, in part, may be due to challenges of therapy development in a heterogeneous patient population. Disruption to protein homeostasis is a key feature of different forms of ALS and FTD. Targeting the endogenous protein chaperone system, the heat shock response (HSR) may, therefore, be a potential therapeutic approach. We conducted a preclinical study of a known pharmacological amplifier of the HSR, called arimoclomol, in mice with a mutation in valosin-containing protein (VCP) which causes both ALS and FTD in patients. We demonstrate that amplification of the HSR ameliorates the ALS/FTD-like phenotype in the spinal cord and brain of mutant VCP mice and prevents neuronal loss, replicating our earlier findings in the SOD1 mouse model of ALS. Moreover, in human cell models, we demonstrate improvements in pathology upon arimoclomol treatment in mutant VCP patient fibroblasts and iPSC-derived motor neurons. Our findings suggest that targeting of the HSR may have therapeutic potential, not only in non-SOD1 ALS, but also for the treatment of FTD.
- 29 July 2023
- Published by Springer Nature in Molecular Neurobiology
- Vol. 60 (12) , 6896-6915
Open AccessAmplifying the Heat Shock Response Ameliorates ALS and FTD Pathology in Mouse and Human Models
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are now known as parts of a disease spectrum with common pathological features and genetic causes. However, as both conditions are clinically heterogeneous, patient groups may be phenotypically similar but pathogenically and genetically variable. Despite numerous clinical trials, there remains no effective therapy for these conditions, which, in part, may be due to challenges of therapy development in a heterogeneous patient population. Disruption to protein homeostasis is a key feature of different forms of ALS and FTD. Targeting the endogenous protein chaperone system, the heat shock response (HSR) may, therefore, be a potential therapeutic approach. We conducted a preclinical study of a known pharmacological amplifier of the HSR, called arimoclomol, in mice with a mutation in valosin-containing protein (VCP) which causes both ALS and FTD in patients. We demonstrate that amplification of the HSR ameliorates the ALS/FTD-like phenotype in the spinal cord and brain of mutant VCP mice and prevents neuronal loss, replicating our earlier findings in the SOD1 mouse model of ALS. Moreover, in human cell models, we demonstrate improvements in pathology upon arimoclomol treatment in mutant VCP patient fibroblasts and iPSC-derived motor neurons. Our findings suggest that targeting of the HSR may have therapeutic potential, not only in non-SOD1 ALS, but also for the treatment of FTD.